Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Background: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Background The treatment landscape for multiple sclerosis (MS) is quickly evolving.
Understanding real-world treatment patterns of patients is necessary to identifying potential …

Background: Patients with multiple sclerosis (MS) require long-term therapy and have a
wide variety of needs for health-related support. The efficacy and safety of MS therapy, as …

Over the last decade, clinical registries have significantly contributed to the pool of evidence
that supports management decisions in patients with multiple sclerosis. Being the largest …

Background and purpose Up‐to‐date information is needed on the extent to which
neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly evolving …

Objective The objective of this study was to describe and compare health care resource
utilization (HCRU) and disease modifying treatment (DMT) use among US adults< 65 years …

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Background Healthcare-utilization data for multiple sclerosis (MS) are scarce in Germany.
The Purpose of the study was to analyse administrative prevalence of MS, medication use …